Clinical Research From HRS Validates AliveCor Delivers Value-Based Care for Heart Health

Multiple Studies Spotlight Clinical Accuracy, Cost Effectiveness, Ease-of-Use and Patient Engagement

SAN FRANCISCO, CA–(Marketwired - May 18, 2016) - AliveCor, the leader in FDA-cleared mobile electrocardiogram (ECG) technology for mobile devices, today announced that its flagship product, Kardia Mobile, was the subject of 9 clinical research presentations at Heart Rhythm Society's 37th Annual Scientific Sessions, the preeminent conference for cardiac electrophysiologists. The research spans a range of clinical applications and shows that Kardia Mobile by AliveCor delivers the same or better readings than traditional ECG options, reduces costs for physicians and patients, and is embraced by caregivers and patients because it is convenient, inexpensive, and easy to use. AliveCor is using advanced mobile and cloud technology to change the dynamic in cardiac care, enabling patients and doctors worldwide to proactively manage heart health, anywhere anytime. Kardia Mobile enables patients and their care teams to more easily and cost-effectively diagnose and manage cardiac arrhythmias such as Atrial Fibrillation (AF).

“AliveCor's vision is to improve the standard of cardiac care while reducing the costs associated with that care and this research shows we are delivering on those goals – helping doctors and patients proactively manage heart health,” said Dr. David Albert, Founder and Chief Medical Officer at AliveCor. “AliveCor is empowering patients to be more participatory in their care while meeting the same rigor and scientific validity as in-hospital tests and other legacy technology. Kardia Mobile is the most clinically-validated, FDA-cleared mobile ECG solution, and is poised to lead this next evolution in health care, significantly changing how medicine is practiced and how patients are treated.” The research demonstrates that Kardia Mobile gives patients more control over their care and makes it easier for health practitioners to detect and treat heart conditions. Instead of making a trip to the hospital or doctor's office for a time-intensive ECG, in 30 seconds Kardia Mobile provides an accurate recording and instant analysis. Even more importantly, Kardia Mobile enables patients to be monitored for symptomatic arrhythmias outside of a hospital or clinic, without having to wear a conventional ambulatory ECG recorder. Both the studies presented at the 2016 HRS meeting and other previously published papers have shown that Kardia is as effective at diagnosing the cause of symptomatic arrhythmias or palpitations. In addition, using Kardia is both less expensive and significantly better accepted by patients than either conventional looping event recorders or Holter monitors.

Kardia Mobile was found to be as good as, and in some situations, superior to traditional testing and legacy monitoring solutions for diagnosing the cause of palpitations. Key presentations include:

Kardia Mobile Superior to Conventional Monitoring: Researchers at the Leeds General Infirmary found that Kardia Mobile is superior to conventional Holter monitoring in patients with palpitations, providing a higher diagnostic yield, more detected arrhythmias, with a similar workload. Kardia Mobile Leads to Improved Patient Compliance: Researchers at the University at Buffalo found that Kardia Mobile provides a diagnostic yield comparable to a 30-day ambulatory looping event monitor and that the smartphone-based ECG monitor can be used as a first approach for the diagnosis of palpitations.

Kardia Mobile provided more information resulting in changes in arrhythmia patient management than traditional external event recorders in a study from researchers at the University of Miami.

AliveCor's AF algorithm was reported to be superior by researchers at Arizona State University to the patient's own ability to detect AF via symptoms.

Kardia Mobile is currently used by physicians at top cardiovascular health systems in the US. For more information:

About AliveCor, Inc.

AliveCor, Inc. is pioneering the creation of FDA-cleared ‘machine learning’ techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared Kardia Mobile is the most clinically validated mobile ECG solution on the market and is recommended by leading cardiologists and used by people worldwide for accurate ECG recordings. This simple to use mobile device and app-based service provides instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an ECG. AliveCor was recognized as a 2015 Tech Pioneer by the World Economic Forum and one of the 50 Smartest Companies in 2015 by the MIT Technology Review (#14). AliveCor is a privately-held company headquartered in San Francisco, Calif. For more information, please visit

AliveCor is a trademark of AliveCor, Inc., registered in the U.S. and other countries.

For more information on where to buy Kardia Mobile please visit

For more information on partnership inquiries, please contact the following: